At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
In Brief
A Phase 2 clinical trial evaluating Trilaciclib, Placebo, and 3 other interventions for Small Cell Lung Cancer. Completed, enrolled 107 participants across 45 sites in 7 countries.
Detailed Summary
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing antitumor efficacy when administered with carboplatin, etoposide, and atezolizumab (E/P/A) therapy in first line treatment for patients with newly diagnosed extensive-stage SCLC. The study was a randomized, double-blinded, placebo-controlled design. Approximately, 100 patients were randomized to trilaciclib + E/P/A or placebo + E/P/A in the study.
Study Details
Timeline
Interventions
Trilaciclib IV
Placebo IV
Carboplatin IV
Etoposide IV
Atezolizumab IV